Skip to main content
HR 3206 112th Congress House

Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011

Official title: To amend the Federal Food, Drug, and Cosmetic Act with respect to appointments to advisory committees and conflicts of interest.

Introduced: December 16, 2011 See on congress.gov
Health Advisory bodiesDepartment of Health and Human ServicesDrug safety, medical device, and laboratory regulationFood and Drug Administration (FDA)
More subjectsShow fewer subjects
Government ethics and transparency, public corruptionHealth technology, devices, supplies
Sign in to write a letter Sign in to watch
This bill died when the 112th Congress ended
It never became law before the 112th Congress (2011–2012) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Oct 18, 2011
Referred to the Subcommittee on Health.
Oct 14, 2011
Introduced in House
Oct 14, 2011
Referred to the House Committee on Energy and Commerce.
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action October 18, 2011

Referred to the Subcommittee on Health.

 Plain-English summary Congressional Research Service

Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011 - Amends the Federal Food, Drug, and Cosmetic Act to revise provisions related to financial interests of Food and Drug Administration (FDA) advisory committee members to require the Secretary of Health and Human Services (HHS) to ensure that individual appointments to advisory committees are made to promote scientific and technical expertise while at the same time minimizing any potential conflicts of interest. Requires the Secretary to consider, with respect to any financial interest constituting a potential conflict of interest, the type, nature, and magnitude of the financial interest. Declares that no specific factor shall be dispositive in the Secretary's evaluation of a particular financial interest.

Repeals the prohibition specifically applicable to FDA that prevents a member of an advisory committee from participating with respect to a particular matter if such individual or an immediate family member of such individual has a financial interest that could be affected by the advice given to the Secretary.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 2
 Cosponsors 14
All 14 Republican 5
Barrow, John
· Jan 31, 2012
MATHESON, JIM
· Jan 31, 2012
Rokita, Todd
· Jan 24, 2012
 R
McCaul, Michael T.
Texas · Dec 16, 2011
WALDEN, GREG
· Nov 3, 2011
CULBERSON, JOHN
· Oct 27, 2011
BILBRAY, BRIAN
· Oct 14, 2011
 R
Blackburn, Marsha
Tennessee · Oct 14, 2011
 R
Cassidy, Bill
Louisiana · Oct 14, 2011
Gingrey, Phil
· Oct 14, 2011
 R
Guthrie, Brett
Kentucky · Oct 14, 2011
 R
Latta, Robert E.
Ohio · Oct 14, 2011
Paulsen, Erik
· Oct 14, 2011
SHIMKUS, JOHN
· Oct 14, 2011
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 3206: Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011. 112th Congress. Open America. https://openamerica.io/bill/112-HR-3206/
MLA
"H.R. 3206: Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011." 112th Congress, 2026, Open America, https://openamerica.io/bill/112-HR-3206/.
Bluebook (legal)
H.R. 3206, 112th Cong. (2026), https://openamerica.io/bill/112-HR-3206/.
Markdown link
[H.R. 3206: Cultivating Scientific Expertise to Foster Innovation for Patients Act of 2011](https://openamerica.io/bill/112-HR-3206/)
Report a problem